Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 26, Issue 3, 2002, Pages 553-560

  Subramanian, Natarajan ^a   Kalkman, Hans O ^a,b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NONE   (Switzerland)

Author keywords

Antipsychotic; Iloperidone; Metabolites; Pharmacology; Receptor

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; DOPAMINE 2 RECEPTOR; DRUG METABOLITE; ILOPERIDONE; P 88 8991; P 95 12113; PD 88 8991; PD 95 12113; RADIOLIGAND; RECEPTOR SUBTYPE; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; MALE; NONHUMAN; RAT; RECEPTOR AFFINITY; SCHIZOPHRENIA;

3T3 CELLS; ANIMALS; ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; CELL LINE; CHO CELLS; CRICETINAE; HUMANS; ISOXAZOLES; MALE; MICE; PIPERIDINES; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN;

EID: 0036199878     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(01)00307-4     Document Type: Article

References (30)

1. 2C-Adrenoceptor-overexpressing mice are impaired in executing non-spatial and spatial escape strategies
2. Efficacy of 4 mg/day and 8 mg/day iloperidone (HP873) administered to schizophrenic patients for 42 days
3. Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia
4. 50) of an enzymatic reaction
5. Pharmacokinetics of HP 873, a potential atypical antipsychotic, in rats and dogs
6. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response
7. Iloperidone: Preclinical profile and early clinical evaluation
8. Iloperidone (HP 873): A study of safety and tolerance in schizophrenic inpatients
9. Dopamine in schizophrenia: A review and reconceptualization
10. Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia
11. 2 adrenoceptor blockade
12. Molecular approaches to receptor targets for drug discovery
13. 2A adrenergic receptor abolishes the antiepileptogenic action of endogenous norepinephrine
14. Extended radioligand binding profile of iloperidone: A broad spectrum dopamine/serotonin/norepinephrine antagonist for the management of psychotic disorders
15. The Clozaril collaborative study group. Clozapine for the treatment-resistant schizophrenic
16. 2 receptor explain the action of atypical antipsychotics?: A new hypothesis
17. Iloperidone binding to human and rat dopamine and 5-HT receptors
18. 2-adrenoceptor antagonists
19. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine
20. i values
21. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study
22. Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome p450 isoforms involved in the metabolism of iloperidone
23. Application of hyphenated LC/NMR and LC/MS techniques in rapid identification of in vitro and in vivo metabolites of iloperidone
24. 2-adrenoceptor subtype C in mice affects the development of behavioral despair and stress-induced increase in plasma corticosterone levels
25. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
26. 1-adrenoceptor antagonism
27. Refractory schizophrenia and atypical antipsychotics
28. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum
29. The dopamine hypothesis of schizophrenia: Current status, future prospects
30. Brain region effects of clozapine on amino acid and monoamine transmission